Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10 2021 - 5:30PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that
on September 10, 2021, the Compensation Committee of Mirum’s Board
of Directors granted non-qualified stock option awards to purchase
an aggregate of 87,500 shares of common stock to ten new employees
under Mirum’s 2020 Inducement Plan. The Compensation Committee of
Mirum’s Board of Directors approved the awards as an inducement
material to the new employees’ employment in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
$18.21 per share, Mirum’s closing trading price on September 10,
2021, and will vest over four years, with 25% of the underlying
shares vesting on the one-year anniversary of the applicable
vesting commencement date and the balance of the underlying shares
vesting monthly thereafter over 36 months, subject to the new
employees’ continued service relationship with Mirum through the
applicable vesting dates. The awards are subject to the terms and
conditions of Mirum’s 2020 Inducement Plan and the terms and
conditions of an applicable award agreement covering the grant.
About Mirum
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. Mirum’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA
for maralixibat in the treatment of cholestatic pruritus in
patients with ALGS. The NDA has been accepted for priority review
by the FDA with a PDUFA action date of September 29, 2021.
Additionally, Mirum’s marketing authorization application for the
treatment of pediatric patients with PFIC2 has been accepted for
review (validated) by the European Medicines Agency. Mirum is also
developing volixibat, also an oral ASBT-inhibitor, in primary
sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and
primary biliary cholangitis. For more information, visit
MirumPharma.com.
To augment its pipeline in cholestatic liver disease, Mirum has
acquired the exclusive option to develop and commercialize two gene
therapy programs, VTX-803 and VTX-802 for PFIC3 and PFIC2,
respectively, from Vivet Therapeutics, following preclinical
evaluation and IND-enabling studies.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005551/en/
Investor Contacts: Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024
